AC Immune (NASDAQ:ACIU) Given Average Recommendation of “Hold” by Brokerages

Posted by on Aug 20th, 2026

AC Immune (NASDAQ:ACIU – Get Free Report) has earned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.50.

Several analysts have weighed in on ACIU shares. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. Finally, BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Wednesday, August 5th.

Get Our Latest Stock Analysis on ACIU

Hedge Funds Weigh In On AC Immune

A number of large investors have recently added to or reduced their stakes in ACIU. Arrowstreet Capital Limited Partnership raised its stake in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. EFG International AG acquired a new position in AC Immune in the 4th quarter valued at $41,000. Marshall Wace LLP acquired a new stake in shares of AC Immune in the 4th quarter worth $586,000. Finally, Goldman Sachs Group Inc. grew its position in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after acquiring an additional 5,920 shares during the period. 51.36% of the stock is currently owned by institutional investors.

AC Immune Stock Up 0.4%

AC Immune stock opened at $2.58 on Thursday. The firm’s 50-day simple moving average is $2.40 and its 200 day simple moving average is $2.71. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93. The stock has a market cap of $262.57 million, a PE ratio of -4.78 and a beta of 1.59. AC Immune has a fifty-two week low of $2.03 and a fifty-two week high of $4.00.

AC Immune (NASDAQ:ACIU – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The business had revenue of $18.67 million during the quarter, compared to the consensus estimate of $9.59 million. Research analysts predict that AC Immune will post -0.6 EPS for the current fiscal year.

About AC Immune

(Get Free Report)

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

Featured Articles

Analyst Recommendations for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.